Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | PAM | P19021 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | CES2 | O00748 | 3/20 | 0.41 |
| ▸ | CES1 | P23141 | 3/20 | 0.41 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.40 |
| ▸ | NAAA | Q02083 | 1/20 | 0.40 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.39 |
| ▸ | PPARG | P37231 | 2/20 | 0.39 |
| ▸ | PPARD | Q03181 | 2/20 | 0.39 |
| ▸ | PPARA | Q07869 | 2/20 | 0.39 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.39 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.39 |
| ▸ | TLR2 | O60603 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3634120 | 1.00 | DGKA (0.47) | DGKALMNAPAMMAPTMAPK1 | |
| SCHEMBL15874693 | 1.00 | DGKA (0.47) | DGKALMNAPAMMAPTMAPK1 | |
| SCHEMBL31051576 | 1.00 | DGKA (0.47) | DGKALMNAPAMMAPTMAPK1 | |
| SCHEMBL17085777 | 1.00 | DGKA (0.47) | DGKALMNAPAMMAPTMAPK1 | |
| SCHEMBL5393249 | 1.00 | DGKA (0.47) | DGKALMNAPAMMAPTMAPK1 | |
| SCHEMBL1982508 | 0.98 | DGKA (0.46) | DGKALMNAPAMMAPTMAPK1 | |
| SCHEMBL1987495 | 0.98 | DGKA (0.46) | DGKALMNAPAMMAPTMAPK1 | |
| SCHEMBL22325614 | 0.98 | DGKA (0.46) | DGKALMNAPAMMAPTMAPK1 | |
| Potassium SCHEMBL31028519 | 0.98 | DGKA (0.46) | DGKALMNAPAMMAPTMAPK1 | |
| SCHEMBL22325596 | 0.98 | DGKA (0.46) | DGKALMNAPAMMAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260076887-A1 | PERSONAL CARE COMPOSITIONS CONTAINING TAILORED MONOLIPID-RHAMNOLIPIDS AND SULFATE-FREE SURFACTANTS | PROCTER & GAMBLE (US) | 2026-03-19 | — | — | US | claimed |
| EP-4676435-A1 | PERSONAL CARE COMPOSITION | The Procter & Gamble Company (US) | 2026-01-14 | — | — | EP | claimed |
| EP-4676436-A1 | PERSONAL CARE COMPOSITION | The Procter & Gamble Company (US) | 2026-01-14 | — | — | EP | claimed |
| US-20250268805-A1 | PERSONAL CARE COMPOSITIONS CONTAINING TAILORED MONOLIPID-RHAMNOLIPIDS AND SULFATE-FREE SURFACTANTS | THE PROCTER & GAMBLE COMPANY | 2025-08-28 | — | — | US | claimed |
| EP-4203914-B1 | ORAL CARE COMPOSITIONS COMPRISING ASCORBIC ACID DERIVATIVES | COLGATE PALMOLIVE CO (US) | 2025-05-07 | — | — | EP | claimed |
| EP-3562464-B1 | COMPOSITIONS COMPRISING TAURATE SURFACTANTS AND METHODS OF USING THE COMPOSITIONS | COLGATE PALMOLIVE CO (US) | 2024-10-09 | — | — | EP | claimed |
| US-20240299272-A1 | PERSONAL CARE COMPOSITION | THE PROCTER & GAMBLE COMPANY | 2024-09-12 | — | — | US | claimed |
| WO-2024187075-A1 | PERSONAL CARE COMPOSITION | THE PROCTER & GAMBLE COMPANY (US) | 2024-09-12 | — | — | WO | claimed |
| US-20240299285-A1 | PERSONAL CARE COMPOSITION | THE PROCTER & GAMBLE COMPANY | 2024-09-12 | — | — | US | claimed |
| WO-2024187076-A1 | PERSONAL CARE COMPOSITION | THE PROCTER & GAMBLE COMPANY (US) | 2024-09-12 | — | — | WO | claimed |
| EP-3551162-B1 | COMPOSITION SUITABLE FOR CLEANSING | OREAL (FR) | 2024-06-26 | — | — | EP | claimed |
| CN-116367814-A | Styling shampoo compositions | 巴斯夫欧洲公司 | 2023-06-30 | — | — | CN | claimed |
| CN-109044881-A | A kind of pearl shining shampoo composition and a kind of preparation method of pearl shining shampoo composition | 花安堂生物科技集团有限公司 | 2018-12-21 | — | — | CN | claimed |
| JP-11180838-A | — | — | None | — | — | JP | disclosed |
| WO-2026089928-A1 | PERSONAL CARE COMPOSITIONS COMPRISING TAURATE SURFACTANT | COLGATE-PALMOLIVE COMPANY (US) | 2026-04-30 | — | — | WO | disclosed |
| EP-4731173-A1 | COMPOSITION COMPRISING LOW MOLECULAR WEIGHT POLYLYSINE AND GLYCOLIPIDS | L'OREAL (FR) | 2026-04-29 | — | — | EP | disclosed |
| EP-1352625-A1 | Cosmetic composition | Kao Corporation (JP) | 2003-10-15 | — | — | EP | disclosed |
| US-20020192177-A1 | Hair tonic composition | A. AOKI, ISHIDA & ASSOCIATES | 2002-12-19 | — | — | US | disclosed |
| EP-0998907-A1 | Hair tonic composition comprising adenosine | SHISEIDO COMPANY LIMITED (JP) | 2000-05-10 | — | — | EP | disclosed |
| JP-H11180838-A | COMPOSITION FOR ORAL CAVITY | LION CORP | 1999-07-06 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250268805-A1 | PERSONAL CARE COMPOSITIONS CONTAINING TAILORED MONOLIPID-RHAMNOLIPIDS AND SULFATE-FREE SURFACTANTS | SMURF1, CUTA, SMURF2 | DGKA 810/4885LMNA 3581/4885PAM 2895/4885 |
| US-20240299272-A1 | PERSONAL CARE COMPOSITION | TAF1, POLH, KAT7 | DGKA 2670/4885LMNA 1353/4885PAM 2267/4885 |
| US-20260076887-A1 | PERSONAL CARE COMPOSITIONS CONTAINING TAILORED MONOLIPID-RHAMNOLIPIDS AND SULFATE-FREE SURFACTANTS | CUTA, PHOSPHO1, MGLL | DGKA 2226/4885LMNA 2819/4885PAM 2814/4885 |
| US-20240299285-A1 | PERSONAL CARE COMPOSITION | KAT7, SMURF1, CUTA | DGKA 2070/4885LMNA 2202/4885PAM 3662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.